2018, CMS and Medicaid - Cardiovascular Update

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2018

CMS

Medicaid

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

MAY 2, 2024

The CardiAMP cell therapy trials for the indications of both chronic myocardial ischemia and ischemic heart failure are covered by the Center for Medicare and Medicaid for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

Ischemia

Ischemia Angina Heart Failure Outcomes

Abstract 280: Risk Factors in 90day Ischemic Stroke Readmissions

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Study Population includes all patients with an ischemic stroke inpatient admission in 2018 and were continuously enrolled with Medicare FFS for 1 year prior to and following their initial 2018 stroke admission. Fewer females and white individuals had a 90‐day readmission (53.5% female and 83.1% in study population).

Risk Factors

Risk Factors Stroke Strokes Medicare

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Abstract 280: Risk Factors in 90day Ischemic Stroke Readmissions

Stay Connected